OTCMKTS:GNMSF

Genmab A/S Q1 2025 Earnings Results & Report

Genmab A/S logo
$515.00 -0.53 (-0.10%)
As of 09:31 AM Eastern

Genmab A/S beat analyst expectations on both earnings and revenue in its Q1 2025 results, released May 8, 2025. The company reported EPS of $3.05 versus the $1.88 consensus estimate, while revenue of $765.14 million topped the $761.09 million estimate by $4.05 million.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens

Genmab A/S EPS Results

Actual EPS
$3.05
Consensus EPS
$1.88
Beat/Miss
Beat by +$1.17
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 5 quarters

Genmab A/S Revenue Results

Actual Revenue
$765.14 million
Expected Revenue
$761.09 million
Beat/Miss
Beat by +$4.05 million
YoY Revenue Growth
N/A

Conference Call Resources

Genmab A/S Q1 2025 Earnings FAQ

Genmab A/S (OTCMKTS:GNMSF) reported earnings of $3.05 per share for Q1 2025, beating the consensus estimate of $1.88. The report was announced on Thursday, May 8, 2025.

Genmab A/S reported revenue of $765.14 million for Q1 2025, against a consensus estimate of $761.09 million.

Genmab A/S Earnings Headlines

Genmab Files Articles of Association Dated November 10
Genmab Reports November 10 Executive Share Sales
The next convergence is here
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This past May, flooding cut the supply route into the largest uranium complex on the planet, and in July Cigar Lake went down a second time. Gerardo Del Real calls this the Third Convergence Event and has backed three small companies positioned in front of it.tc pixel
Genmab Gains After Phase 3 Ovarian Cancer Win for Rina-S
See More Genmab A/S Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Genmab A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Genmab A/S and other key companies, straight to your email.

About Genmab A/S

Genmab A/S (OTCMKTS:GNMSF) is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on treatments for cancer and other serious diseases.

The company uses its antibody technologies, including DuoBody and HexaBody, to develop therapeutic candidates and works with pharmaceutical partners to advance and commercialize medicines. Products developed through Genmab programs include Darzalex, Tecvayli, Epkinly/Tepkinly and Rybrevant, which are marketed through partnerships.

Genmab conducts research and development internationally, with operations in Europe, North America and Asia. The company is led by President and Chief Executive Officer Jan van de Winkel, who co-founded Genmab.

View Genmab A/S Profile